This paper assesses the role that pharmacy benefit managers (PBMs) could play in facilitating improved Medicare beneficiary access to pharmaceutical care (which includes access to pharmaceuticals as well as disease management coverage). Based on a literature review and original survey results,...

Although Medicare risk plans have been withdrawn in a number of US geographical areas, the size and dollar value associated with the senior demographic group is too large for health plans to ignore. Unlike other developed nations, the US government offers to Medicare-eligible citizens a choice...

Objective: Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of foreign countries. Our objective is to quantify the theoretical cross-border spill-over effects of cross-reference pricing schemes on pharmaceutical prices in the former EU-15...

This article reviews policies on physician payment methods that Organisation for Economic Cooperation and Development (OECD) countries have implemented to promote an efficient deployment of physicians. Countries

This article analyses 3 areas of policy that could reduce the fragmentation and improve the competitiveness of the European pharmaceutical sector. It argues that a potential solution to the issue of fragmentation of pharmaceutical research, development and innovation may be the development of...

Documented launch delays and the ensuing debate over their underlying causes have focused on assessment from the individual country's perspective. Seen in a larger game theoretical framework this may cause problems, because although the countries see an individual game, the pharmaceutical firm...

Pharmaceutical manufacturers have increased the availability of their products and sometimes increased their own financial returns by charging lower prices outside of the US and by discounting to lower-income patients in the US. Examples include discounted HIV-AIDS drugs in developing countries...